<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03660683</url>
  </required_header>
  <id_info>
    <org_study_id>180295</org_study_id>
    <nct_id>NCT03660683</nct_id>
  </id_info>
  <brief_title>Effect of Saxagliptin and Dapagliflozin on Endothelial Progenitor Cell in Patients With Type 2 Diabetes Mellitus</brief_title>
  <official_title>Cardio-Protective of Effect of Saxagliptin and Dapagliflozin Combination on Endothelial Progenitor Cells in Patients With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sabyasachi Sen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>George Washington University</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Investigator hypothesize that Dapagliflozin will improve EPC number and function AND&#xD;
      Saxagliptin in addition to Dapagliflozin (additive effect) may improve EPC number and&#xD;
      function even more than Dapa alone, compared to placebo.&#xD;
&#xD;
      The Investigator propose a 3-arm randomized, parallel group, longitudinal study of 16-week&#xD;
      intervention duration. Participants will be randomized to 3 groups:&#xD;
&#xD;
      Group A: Dapa (10 mg) + Saxa Placebo, Enroll n=15, retain n=12 Group B: Dapa (10 mg) + Saxa&#xD;
      (5 mg), Enroll n=15, retain n=12 Group C: Dapa Placebo + Saxa Placebo, Enroll n=15, retain&#xD;
      n=12&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Investigator hypothesize that Dapagliflozin will improve EPC number and function AND&#xD;
      Saxagliptin in addition to Dapagliflozin may have an additive effect to improve EPC number&#xD;
      and function even more than Dapa alone, compared to placebo.&#xD;
&#xD;
      In this proposal the investigator plan to conduct a placebo matched study with type 2&#xD;
      diabetes subjects on any doses of metformin or Insulin or a combination of both and has no&#xD;
      history of DPP4 ( Dipeptidyl Peptidase-4) DPP4 inhibitor, incretin mimetic or SGLT2 inhibitor&#xD;
      intake history. Participants will have known macrovascular complications (such as&#xD;
      Cardiovascular Disease (CVD), Cerebrovascular Accident (CVA), and Peripheral Vascular Disease&#xD;
      (PVD).&#xD;
&#xD;
      3 STUDY OBJECTIVES&#xD;
&#xD;
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      CELLULAR BIOMARKER OF ENDOTHELIUM&#xD;
&#xD;
      The primary objective is to ascertain if 16 weeks of Dapa or Dapa+Saxa Combo therapy will&#xD;
      improve :&#xD;
&#xD;
      CD34+ cell number, CD34+ migratory function and CD34+ gene expression in type 2 diabetes with&#xD;
      CVD.&#xD;
&#xD;
      SECONDARY OBJECTIVE:&#xD;
&#xD;
      ARTERIAL STIFFNESS AND RENAL FUNCTION, NON-CELLULAR MARKERS OF ENDOTHELIUM To determine&#xD;
      whether use of Dapa or Dapa+Saxa Combo alters markers of endothelial function such as:&#xD;
      arterial stiffness measures (via tonometry), biochemical measures derived from plasma,&#xD;
      pertaining to endothelial function (hs-CRP, IL-6, TNF-alpha), renal function such as&#xD;
      proteinuria (microalbumin/creatinine ratio) and urine exosome study to determine podocyte&#xD;
      health. The secondary measures are indirect measures of endothelial inflammation in early&#xD;
      type 2 diabetes patients.&#xD;
&#xD;
      Effect on Arterial Stiffness:&#xD;
&#xD;
      I. Pulse Wave Analysis and Vascular Flow will be assessed using SphygmoCor CP system from&#xD;
      ATCOR as a measure of central arterial pressure and arterial stiffness.&#xD;
&#xD;
      II. Vessel health will be assessed by degree of arterial stiffness, using arterial tonometry.&#xD;
&#xD;
      III. The central and the aortic pressure is assessed by pulse wave analysis (PWA) and pulse&#xD;
      wave velocity (PWV).&#xD;
&#xD;
      Effect on Blood Biochemistry:&#xD;
&#xD;
      The Investigator believes cell based biomarkers are superior to traditional serum and plasma&#xD;
      biomarkers and the outcome report will be stronger if one can show positive correlation&#xD;
      between the two outcome measures. The Investigator therefore will be looking at:&#xD;
&#xD;
      I. Inflammation, apoptosis and anti-oxidant protein levels: Highly selective C-reactive&#xD;
      protein (hs-CRP), IL-6, TNF-alpha.&#xD;
&#xD;
      II. Plasma SDF1 alpha (ELISA) and GLP-1 and Ghrelin (ELISA) will be estimated to assess&#xD;
      endothelial health and factors that may influence CD34+ cell chemotaxis III. Podocyte health&#xD;
      via urine exosome analysis. IV. The glomerular filtration rate (GFR) will be estimated by&#xD;
      MDRD equation.&#xD;
&#xD;
      a. GFR = 141 X min (Scr/κ,1)α X max(Scr/κ,1)-1.209 X 0.993Age X 1.018 [if female] X 1.159 [if&#xD;
      African American]; where Scr is serum creatinine (mg/dL), κ is 0.7 for females and 0.9 for&#xD;
      males, α is -0.329 for females and -0.411 for males, min indicates the minimum of Scr/κ or 1,&#xD;
      and max indicates the maximum of Scr/κ or 1.32&#xD;
&#xD;
      TERTIARY OBJECTIVE:&#xD;
&#xD;
      METABOLISM MARKERS The tertiary objective is to determine whether use of Dapa or Dapa+Saxa&#xD;
      Combo alters body composition, fasting lipid profile, and levels of insulin, glucose, and&#xD;
      appetite controlling hormones.&#xD;
&#xD;
      Effect on Blood Biochemistry:&#xD;
&#xD;
      The Investigator believes cell based biomarkers are superior to traditional serum and plasma&#xD;
      biomarkers and the outcome report will be stronger if one can show positive co-relation&#xD;
      between the two outcome measures.&#xD;
&#xD;
      I. Fasting glucose, and insulin. a. Glycemic control will be evaluated by measuring fasting&#xD;
      blood glucose, insulin levels and HbA1c. Fasting blood glucose, insulin and lipid profile&#xD;
      will be used to assess insulin resistance.28,31 II. Lipid profile III. Appetite controlling&#xD;
      hormones via LabCorp: Leptin, Adiponectin IV. Appetite controlling hormones, via ELISA: GLP1,&#xD;
      Ghrelin&#xD;
&#xD;
      Effect of Dapa and Dapa+Saxa Combo on Body Habitus (Determination of body composition and&#xD;
      visceral fat) The Investigator plans to study cardio-metabolic effect of Dapa and Dapa+Saxa&#xD;
      Combo.&#xD;
&#xD;
      I. Using body composition scale:&#xD;
&#xD;
        1. Height and weight will be measured and the body mass index (BMI=kgm2) used as an&#xD;
           indicator of relative weight.&#xD;
&#xD;
        2. The body composition scale calculates body fat%, total body water%, fat free mass, etc.,&#xD;
           in addition to BMI.&#xD;
&#xD;
           The secondary outcome markers (arterial stiffness and renal outcome measures) and&#xD;
           tertiary outcome markers (serum biochemistry) are crucial in order to corroborate the&#xD;
           cellular findings with currently accepted clinical efficacy outcome measures such as&#xD;
           arterial stiffness and serum biochemistry. This design is similar to our recently&#xD;
           published manuscript on Saxagliptin and cellular outcome measures.&#xD;
&#xD;
           4 INVESTIGATIONAL PLAN&#xD;
&#xD;
           STUDY DESIGN AND DURATION&#xD;
&#xD;
           +/- 6 day window for visits&#xD;
&#xD;
           *Assessed at week 0, 8 and 16: Primary, Secondary &amp; Tertiary Outcomes.&#xD;
&#xD;
           Week 20: A telephone call to subjects will be made 4 weeks after last dose of study&#xD;
           medication to determine if there have been any adverse events.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 22, 2018</start_date>
  <completion_date type="Anticipated">July 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CD 34+ Cell Number</measure>
    <time_frame>16 weeks</time_frame>
    <description>Cluster Designation 34+ Cell Number</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CD 34+ Cell Migratory Function</measure>
    <time_frame>16 weeks</time_frame>
    <description>Cell Migration throught SDF1a</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CD 34+ Cell Gene Expression in T2Dm with CVD</measure>
    <time_frame>16 weeks</time_frame>
    <description>Gene Expression</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Arterial Stiffness</measure>
    <time_frame>16 Weeks</time_frame>
    <description>via tonometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Biochemistries</measure>
    <time_frame>16 Weeks</time_frame>
    <description>hs CRP, IL6, TNFa</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal Function</measure>
    <time_frame>16 Weeks</time_frame>
    <description>Micro albumin/ Creatinine Ratio ( Proteinuria)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine Exosome Assay</measure>
    <time_frame>16 Weeks</time_frame>
    <description>Exosomes released from Kidney Podocyte is a indicator of kidney Podocyte health.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Body Fat Percent</measure>
    <time_frame>16 Weeks</time_frame>
    <description>using Tanita B350 Total Body Composition Analyzer</description>
  </other_outcome>
  <other_outcome>
    <measure>Fasting Lipid Profile</measure>
    <time_frame>16 Weeks</time_frame>
    <description>Total Cholesterol, LDL, HDL and VLDL</description>
  </other_outcome>
  <other_outcome>
    <measure>Serum Insulin Level</measure>
    <time_frame>16 Weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Serum Glucose</measure>
    <time_frame>16 Weeks</time_frame>
    <description>HbA1c, Fasting Glucose</description>
  </other_outcome>
  <other_outcome>
    <measure>Appetite Controlling Hormone</measure>
    <time_frame>16 Weeks</time_frame>
    <description>Leptin, Adiponectin, GLP1, Ghrelin</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>Group A Dapa</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dapagliflozin 10 mg + Saxagliptin Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B DapaSaxa</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dapagliflozin 10mg + Saxagliptin 5mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Oral Tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin 10mg</intervention_name>
    <description>Dapagliflozin 10mg PO QD</description>
    <arm_group_label>Group A Dapa</arm_group_label>
    <arm_group_label>Group B DapaSaxa</arm_group_label>
    <other_name>Farxiga</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saxagliptin 5mg</intervention_name>
    <description>Saxagliptin 5 mg PO QD</description>
    <arm_group_label>Group B DapaSaxa</arm_group_label>
    <other_name>Onglyza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>Matching Placebo Tablets</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Able to understand the study, and provide a signed &amp; dated informed consent.&#xD;
&#xD;
          2. Diagnosis of Type 2 diabetes mellitus using criteria of the American Diabetes&#xD;
             Association.&#xD;
&#xD;
          3. 30-70 years old.&#xD;
&#xD;
          4. HbA1C 7 to 10%, both inclusive&#xD;
&#xD;
          5. BMI of 25 - 39.9 kg/m2 both inclusive.&#xD;
&#xD;
          6. Taking a stable dose (for 12 weeks) of Metformin (any dosage) and/or Insulin (any&#xD;
             dosage) for the treatment of T2DM&#xD;
&#xD;
          7. Patients with current Cardiovascular Disease (CVD) in tye 2 diabetes patients, defined&#xD;
             by ≥ 1 of the following:&#xD;
&#xD;
               1. MI &gt;2 months prior&#xD;
&#xD;
               2. Multivessel CAD&#xD;
&#xD;
               3. Angina (intermittent or chronic)&#xD;
&#xD;
               4. Single vessel CAD with positive stress test or UA hospitalization in prior year&#xD;
&#xD;
               5. UA &gt;2 months prior and evidence of CAD&#xD;
&#xD;
               6. Stroke &gt;2 months prior&#xD;
&#xD;
               7. Occlusive PAD&#xD;
&#xD;
               8. Proteinuria of more than 30mg/dl&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Planned CV surgery or angioplasty in 1 month&#xD;
&#xD;
          2. Prior surgery with chronic malabsorption (eg, bariatric) in prior 1 year&#xD;
&#xD;
          3. Diagnosis of Type 1 diabetes mellitus&#xD;
&#xD;
          4. History of GAD antibody positive status&#xD;
&#xD;
          5. Uncontrolled Inflammatory Disease/Inflammatory drug use. **Evaluated by PI on&#xD;
             case-by-case basis**&#xD;
&#xD;
          6. Recent history of diabetic keto-acidosis in the past 3months, or recurrent history of&#xD;
             diabetic ketoacidosis (≥ 3 times)&#xD;
&#xD;
          7. Active bladder cancer&#xD;
&#xD;
          8. Active wounds (e.g. Diabetic ulcers) or recent surgery within 1 month&#xD;
&#xD;
          9. Untreated hyper/hypothyroidism&#xD;
&#xD;
         10. Women of child bearing potential who are not willing to use a contraceptive method to&#xD;
             avoid pregnancy for the 16 weeks of study duration&#xD;
&#xD;
         11. Women who are pregnant or breastfeeding&#xD;
&#xD;
         12. Implanted devices (eg. Pacemaker) that may interact with Tanita scale&#xD;
&#xD;
         13. Any other clinical condition that would jeopardize patients safety while participating&#xD;
             in this clinical trial Concomitant Medications&#xD;
&#xD;
         14. Taking any other oral anti-diabetic agent other than Metformin and/or Insulin for&#xD;
             their treatment of T2DM&#xD;
&#xD;
         15. Beginning statin medications in the past 1 month or change in statin dose in the past&#xD;
             1 month&#xD;
&#xD;
         16. Use of consistent long-term steroid medication (oral, inhaled, injected) within the&#xD;
             last 1 month&#xD;
&#xD;
         17. Treatment with a strong cytochrome P450 3A4 (CYP34A) or P-gp inducer (ie. Rifampin)&#xD;
&#xD;
         18. Subjects with a history of any serious hypersensitivity reaction to Dapagliflozin /&#xD;
             Saxagliptin or another SGLT-2 inhibitor/ DPP4 inhibitor Laboratory Findings&#xD;
&#xD;
         19. Uncontrolled hyperglycemia, defined as a fasting glucose &gt;240 mg/dL (&gt;13.3 mmol/L) at&#xD;
             screening.&#xD;
&#xD;
         20. Liver disease with ALT, AST or ALP x3 ULN&#xD;
&#xD;
         21. eGFR &lt; 60 mL/min/1.73 m2 by MDRD equation in the past 3 months&#xD;
&#xD;
         22. Clinically significant RBC disorders such as hemoglobinopathies&#xD;
&#xD;
         23. Serum creatinine levels ≥1.8 mg/dL with estimated eGFP &lt; 60 mL/min&#xD;
&#xD;
         24. Triglycerides &gt; 450 mg/dL&#xD;
&#xD;
         25. Baseline Hematuria (judged by a urinalysis dipstick at screening) Social History&#xD;
&#xD;
         26. Active smokers&#xD;
&#xD;
         27. Chronic or persistent alcohol or drug abuse&#xD;
&#xD;
         28. Prisoners or subjects who are involuntarily incarcerated&#xD;
&#xD;
         29. Subjects who are compulsorily detained for treatment of either a psychiatric or&#xD;
             physical (eg. infectious disease) illness&#xD;
&#xD;
         30. Participation in another trial with an investigational drug within 30 days prior to&#xD;
             informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sabyasachi Sen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>GWU</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hassan Awal, MD</last_name>
    <phone>202 741 2389</phone>
    <email>hawal@mfa.gwu.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>The GW Medical Faculty Associates</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hassan Awal, MD</last_name>
      <email>hawal@mfa.gwu.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>August 17, 2018</study_first_submitted>
  <study_first_submitted_qc>September 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 6, 2018</study_first_posted>
  <last_update_submitted>July 22, 2020</last_update_submitted>
  <last_update_submitted_qc>July 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>George Washington University</investigator_affiliation>
    <investigator_full_name>Sabyasachi Sen</investigator_full_name>
    <investigator_title>Associate Professor, Dept. of Medicine (Division of Endocrinology)</investigator_title>
  </responsible_party>
  <keyword>saxagliptin dapagliflozin diabetes cardiovascular diseases EPC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dapagliflozin</mesh_term>
    <mesh_term>Saxagliptin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

